Investor Presentaiton
Clear path to organic growth acceleration in the outer part of the
Strive25 period and beyond with the addition of Kerecis
24
-8%
Strive25
ambition:
10%+ organic
growth in US
Chronic Care
Strive25
ambition:
Double-digit
organic growth
above the
market in China
Chronic Care
Strive25
ambition:
Launch of the
Clinical
Performance
Programme
(Luja™ and Heylo™)
Guidance
FY 22/23
US
China
Innovation
+1%-point
accretion
8-10%
7-9%
Organic growth
of 8-10%
Expected to
become part of
organic growth
as of FY 2024/25
Voice &
Respiratory
Care¹
1
1 Part of organic revenue growth since February 1, 2023
2 The acquisition of Kerecis was announced July 7, 2023. For further details please refer to the announcement: Coloplast acquires Kerecis
2
Strive25 growth
Kerecis
Updated long-
guidance
term growth
guidance
ColoplastView entire presentation